DK2024375T3 - Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere - Google Patents

Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere

Info

Publication number
DK2024375T3
DK2024375T3 DK07761873.4T DK07761873T DK2024375T3 DK 2024375 T3 DK2024375 T3 DK 2024375T3 DK 07761873 T DK07761873 T DK 07761873T DK 2024375 T3 DK2024375 T3 DK 2024375T3
Authority
DK
Denmark
Prior art keywords
indolobenzazepine
hcv
cyclopropyl
condensed
ns5b inhibitors
Prior art date
Application number
DK07761873.4T
Other languages
English (en)
Inventor
John A Bender
Min Ding
Robert G Gentles
Piyasena Hewawasam
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38512732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2024375(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK2024375T3 publication Critical patent/DK2024375T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
DK07761873.4T 2006-05-17 2007-05-04 Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere DK2024375T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80112506P 2006-05-17 2006-05-17
US80200506P 2006-05-19 2006-05-19
US85208406P 2006-10-16 2006-10-16
US89475707P 2007-03-14 2007-03-14
PCT/US2007/068209 WO2007136982A1 (en) 2006-05-17 2007-05-04 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
DK2024375T3 true DK2024375T3 (da) 2011-06-27

Family

ID=38512732

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07761873.4T DK2024375T3 (da) 2006-05-17 2007-05-04 Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere

Country Status (25)

Country Link
US (1) US7456166B2 (da)
EP (1) EP2024375B1 (da)
JP (1) JP5284952B2 (da)
KR (1) KR101417145B1 (da)
AR (1) AR061008A1 (da)
AT (1) ATE501156T1 (da)
AU (1) AU2007253998B2 (da)
BR (1) BRPI0711821A2 (da)
CA (1) CA2651690C (da)
CY (1) CY1111526T1 (da)
DE (1) DE602007013036D1 (da)
DK (1) DK2024375T3 (da)
EA (1) EA015286B1 (da)
HK (1) HK1122814A1 (da)
HR (1) HRP20110194T1 (da)
IL (1) IL195025A (da)
MX (1) MX2008014435A (da)
NO (1) NO341663B1 (da)
NZ (1) NZ572555A (da)
PE (1) PE20080070A1 (da)
PL (1) PL2024375T3 (da)
SI (1) SI2024375T1 (da)
TW (1) TWI401244B (da)
WO (1) WO2007136982A1 (da)
ZA (1) ZA200809548B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2029606B1 (en) * 2006-05-25 2010-05-26 Brystol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
JP5211078B2 (ja) 2007-03-13 2013-06-12 ブリストル−マイヤーズ スクイブ カンパニー シクロプロピル縮合インドロベンズアゼピンｈｃｖｎｓ５ｂ阻害剤
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
ES2375065T3 (es) * 2007-11-20 2012-02-24 Bristol-Myers Squibb Company Inhibidores de indilobenzazepina condensada con ciclopropilo de la ns5b del vhc.
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
WO2009080836A2 (en) * 2007-12-24 2009-07-02 Tibotec Pharmaceuticals Ltd. Macrocyclic indoles as hepatitis c virus inhibitors
MX2010010245A (es) * 2008-03-27 2010-10-05 Bristol Myers Squibb Co Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a dioxolano y dioxolanona.
US8178523B2 (en) * 2008-03-27 2012-05-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2011515484A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ピロリジン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
EP2385838A1 (en) 2009-01-07 2011-11-16 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN103097356B (zh) 2010-06-24 2016-01-13 爱尔兰詹森科学公司 13-环己基-3-甲氧基-6-[甲基-(2-{2-[甲基-(氨磺酰基)-氨基]-乙氧基}-乙基)-氨基甲酰基]-7H-吲哚并-[2,1-a]-[2]-苯并氮杂*-10-羧酸的制备
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8716275B2 (en) * 2011-10-20 2014-05-06 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
EP3091022A3 (en) 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US753137A (en) * 1904-02-23 Dust-pan
US752354A (en) * 1904-02-16 Composition post
US756203A (en) * 1903-11-14 1904-04-05 Oliver E Barthel Muffler.
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
AU2005293821B2 (en) 2004-10-13 2011-05-12 Merck Patent Gmbh N,N'-dithenylurea derivatives used in the form of kinase inhibitors
JP2008517987A (ja) * 2004-10-26 2008-05-29 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス薬としての四環式インドール誘導体
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) * 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents

Also Published As

Publication number Publication date
JP5284952B2 (ja) 2013-09-11
ZA200809548B (en) 2009-12-30
JP2009537557A (ja) 2009-10-29
NO20084637L (no) 2008-12-15
MX2008014435A (es) 2008-11-27
IL195025A0 (en) 2009-08-03
AR061008A1 (es) 2008-07-30
PE20080070A1 (es) 2008-03-10
KR101417145B1 (ko) 2014-07-08
ATE501156T1 (de) 2011-03-15
EP2024375A1 (en) 2009-02-18
TWI401244B (zh) 2013-07-11
EA200802346A1 (ru) 2009-06-30
WO2007136982A1 (en) 2007-11-29
IL195025A (en) 2013-09-30
BRPI0711821A2 (pt) 2012-01-17
EP2024375B1 (en) 2011-03-09
PL2024375T3 (pl) 2011-07-29
US20070270405A1 (en) 2007-11-22
SI2024375T1 (sl) 2011-10-28
DE602007013036D1 (de) 2011-04-21
KR20090008344A (ko) 2009-01-21
HRP20110194T1 (hr) 2011-04-30
AU2007253998A1 (en) 2007-11-29
NZ572555A (en) 2010-11-26
EA015286B1 (ru) 2011-06-30
CA2651690C (en) 2014-11-04
AU2007253998B2 (en) 2012-03-15
US7456166B2 (en) 2008-11-25
CY1111526T1 (el) 2016-02-10
CA2651690A1 (en) 2007-11-29
NO341663B1 (no) 2017-12-18
HK1122814A1 (en) 2009-05-29
TW200804282A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
CY2017016I2 (el) Αναστολεις πρωτεασωματος
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DE602006019782D1 (de) Kapselperforationsmodul
DE602007002544D1 (de) Nuancierungsmittel
DE602007008423D1 (de) Flüssigkeitshärtung
DE602007003893D1 (de) Kippambossanordnung
DE602007006947D1 (de) Pyridopyrimidinonderivate
DE602007000258D1 (de) Kassetteneinspannmechanismus
DE602006020192D1 (de) Riemenscheibenanorndung
DE602007001280D1 (de) Getränkeextraktor
AT504580A3 (de) Scan-einrichtung
DE602007008400D1 (de) Kaliummonopersulfatlösungen
DE602006019150D1 (de) Riemenscheibenanorndung
ATE546437T1 (de) Aminomethyl-4-imidazole
DE502007000218D1 (de) nsetzungen
DE502007002453D1 (de) Kunstoffverdichtergehäuse
DE602007000501D1 (de) Breitbandrichtkoppler
DK2066662T3 (da) Serinhydrolaseinhibitorer
DE602006016174D1 (de) Blisterverpackungsverfahren
DE602007004080D1 (de) Tintenstrahlaufnehmer
DE602007007460D1 (de) Sehkrafttestsystem
DE502007000361D1 (de) Stanznieteinheit
DE602007000333D1 (de) Napfbefestigungsvorrichtung